Key Points
Deploying AI to reduce drug development timelines
Identifying therapeutic targets through advanced data analysis
Enhancing clinical trial processes with generative AI technologies
Strengthening patient-focused medical research strategies
Transforming Drug Development with Advanced Technologies The journey of developing a new drug typically spans nearly 15 years, encompassing extensive research, clinical trials, and eventual distribution to patients. One of the primary challenges in this process is reducing the attrition rate of drug candidates, which is crucial for maximizing success rates and speeding up development, particularly in rare diseases where patient needs are often unmet.
Claude Bertrand, Executive Vice President of Research & Development and Chief Scientific Officer at Servier, emphasized the importance of integrating scientific innovation with digital technologies. "Our partnership with Google Cloud enables us to unlock the potential of AI to reach scientific conclusions more quickly and enhance the productivity of our R&D efforts," he said.
Harnessing AI for Enhanced Research Productivity
Servier's commitment to using AI aims to significantly improve productivity in research and development. By analyzing vast amounts of medical data in real-time, researchers can streamline processes such as identifying therapeutic targets and patient subpopulations that are most likely to benefit from new treatments. Moreover, AI is seen as a powerful ally in developing personalized therapeutic solutions more rapidly.
So far, around 60 use cases for generative AI have been identified within Servier to expedite drug development. These include discovering new therapeutic targets, enhancing screening processes, optimizing clinical trials, and improving supply chain management. Additionally, AI will contribute to reducing environmental impact while strengthening interactions between patients and healthcare professionals.
Commitment to Security and Efficiency
AI is a fundamental part of Servier's digital transformation strategy. The company is introducing a range of tools based on Google Cloud's generative AI technologies, including its Gemini large language models. These tools are designed to enhance the efficiency of Servier's operations while adhering to the highest standards of data security and confidentiality.
Google Cloud will assist Servier in integrating various AI technologies throughout its value chain, ensuring that generated data remains secure and confidential.
Looking Ahead: A Promising Collaboration
Virginie Dominguez, Executive Vice President of Digital Data and Information Systems at Servier, expressed enthusiasm for the extended partnership with Google Cloud. "By deploying Google Cloud AI solutions across our entire value chain, we reaffirm our commitment to innovation in therapeutic progress aimed at accelerating research for patients' benefits," she noted.
Shweta Maniar, global director for Healthcare & Life Sciences at Google Cloud, praised Servier's proactive approach in utilizing AI technology for its R&D programs. "This collaboration promises significant advancements in disease research and treatment in the coming years," she stated.
This renewed partnership builds upon an initial agreement signed in August 2022, which laid the groundwork for robust technological infrastructure within Servier to secure data and enhance AI initiatives. As the collaboration continues for another five years, both organizations are excited about the future possibilities that lie ahead.
